nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—Salbutamol—chronic obstructive pulmonary disease	0.201	1	CrCtD
Salmeterol—asthma—chronic obstructive pulmonary disease	0.178	1	CtDrD
Salmeterol—Adrenergic beta2-Agonists—Arformoterol—chronic obstructive pulmonary disease	0.106	0.333	CiPCiCtD
Salmeterol—Adrenergic beta2-Agonists—Salbutamol—chronic obstructive pulmonary disease	0.106	0.333	CiPCiCtD
Salmeterol—Adrenergic beta2-Agonists—Formoterol—chronic obstructive pulmonary disease	0.106	0.333	CiPCiCtD
Salmeterol—ADRB2—chronic obstructive pulmonary disease	0.0724	1	CbGaD
Salmeterol—Arbutamine—Arformoterol—chronic obstructive pulmonary disease	0.0339	0.306	CrCrCtD
Salmeterol—Arbutamine—Formoterol—chronic obstructive pulmonary disease	0.0339	0.306	CrCrCtD
Salmeterol—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0254	0.302	CbGbCtD
Salmeterol—Labetalol—Arformoterol—chronic obstructive pulmonary disease	0.0215	0.194	CrCrCtD
Salmeterol—Labetalol—Formoterol—chronic obstructive pulmonary disease	0.0215	0.194	CrCrCtD
Salmeterol—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0192	0.229	CbGbCtD
Salmeterol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0192	0.229	CbGbCtD
Salmeterol—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.00573	0.0683	CbGbCtD
Salmeterol—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.00404	0.0482	CbGbCtD
Salmeterol—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00273	0.0326	CbGbCtD
Salmeterol—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00261	0.0311	CbGbCtD
Salmeterol—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00232	0.0277	CbGbCtD
Salmeterol—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00136	0.0163	CbGbCtD
Salmeterol—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00129	0.0153	CbGbCtD
Salmeterol—Arbutamine—ADRB2—chronic obstructive pulmonary disease	0.000171	0.32	CrCbGaD
Salmeterol—Salbutamol—ADRB2—chronic obstructive pulmonary disease	0.000166	0.31	CrCbGaD
Salmeterol—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000156	0.0522	CbGpPWpGaD
Salmeterol—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000138	0.0461	CbGpPWpGaD
Salmeterol—Labetalol—ADRB2—chronic obstructive pulmonary disease	0.000121	0.227	CrCbGaD
Salmeterol—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000113	0.0377	CbGpPWpGaD
Salmeterol—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	9.57e-05	0.0321	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	8.88e-05	0.0298	CbGpPWpGaD
Salmeterol—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	8.71e-05	0.0292	CbGpPWpGaD
Salmeterol—Propafenone—CYP1A2—chronic obstructive pulmonary disease	7.67e-05	0.143	CrCbGaD
Salmeterol—CYP3A7—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	7.35e-05	0.0246	CbGpPWpGaD
Salmeterol—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	6.96e-05	0.0233	CbGpPWpGaD
Salmeterol—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	6.33e-05	0.0212	CbGpPWpGaD
Salmeterol—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	5.72e-05	0.0192	CbGpPWpGaD
Salmeterol—CYP3A5—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	5.53e-05	0.0185	CbGpPWpGaD
Salmeterol—CYP3A7—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	5.34e-05	0.0179	CbGpPWpGaD
Salmeterol—CYP3A5—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	5.31e-05	0.0178	CbGpPWpGaD
Salmeterol—CYP3A5—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	5.11e-05	0.0171	CbGpPWpGaD
Salmeterol—CYP2C8—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	4.6e-05	0.0154	CbGpPWpGaD
Salmeterol—CYP2C8—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	4.42e-05	0.0148	CbGpPWpGaD
Salmeterol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	4.38e-05	0.0147	CbGpPWpGaD
Salmeterol—CYP3A5—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	3.86e-05	0.0129	CbGpPWpGaD
Salmeterol—CYP3A5—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.71e-05	0.0124	CbGpPWpGaD
Salmeterol—ADRB2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	3.43e-05	0.0115	CbGpPWpGaD
Salmeterol—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	3.4e-05	0.0114	CbGpPWpGaD
Salmeterol—CYP2C8—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	3.34e-05	0.0112	CbGpPWpGaD
Salmeterol—CYP2C8—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.21e-05	0.0108	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	3.12e-05	0.0105	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	3.1e-05	0.0104	CbGpPWpGaD
Salmeterol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	3.05e-05	0.0102	CbGpPWpGaD
Salmeterol—Agitation—Arformoterol—chronic obstructive pulmonary disease	3.02e-05	0.000891	CcSEcCtD
Salmeterol—Agitation—Formoterol—chronic obstructive pulmonary disease	3.02e-05	0.000891	CcSEcCtD
Salmeterol—Tremor—Montelukast—chronic obstructive pulmonary disease	3.02e-05	0.00089	CcSEcCtD
Salmeterol—Nervousness—Salbutamol—chronic obstructive pulmonary disease	3.02e-05	0.000889	CcSEcCtD
Salmeterol—CYP3A7—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	3.01e-05	0.0101	CbGpPWpGaD
Salmeterol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	3.01e-05	0.000887	CcSEcCtD
Salmeterol—ADRB2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	3.01e-05	0.0101	CbGpPWpGaD
Salmeterol—Angioedema—Formoterol—chronic obstructive pulmonary disease	3e-05	0.000886	CcSEcCtD
Salmeterol—Angioedema—Arformoterol—chronic obstructive pulmonary disease	3e-05	0.000886	CcSEcCtD
Salmeterol—Back pain—Salbutamol—chronic obstructive pulmonary disease	3e-05	0.000886	CcSEcCtD
Salmeterol—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	2.99e-05	0.000881	CcSEcCtD
Salmeterol—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	2.98e-05	0.00088	CcSEcCtD
Salmeterol—Malaise—Formoterol—chronic obstructive pulmonary disease	2.96e-05	0.000875	CcSEcCtD
Salmeterol—Malaise—Arformoterol—chronic obstructive pulmonary disease	2.96e-05	0.000875	CcSEcCtD
Salmeterol—Agitation—Montelukast—chronic obstructive pulmonary disease	2.96e-05	0.000873	CcSEcCtD
Salmeterol—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	2.95e-05	0.00989	CbGpPWpGaD
Salmeterol—Angioedema—Montelukast—chronic obstructive pulmonary disease	2.94e-05	0.000868	CcSEcCtD
Salmeterol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	2.93e-05	0.000863	CcSEcCtD
Salmeterol—Tremor—Salbutamol—chronic obstructive pulmonary disease	2.91e-05	0.000858	CcSEcCtD
Salmeterol—Palpitations—Arformoterol—chronic obstructive pulmonary disease	2.91e-05	0.000857	CcSEcCtD
Salmeterol—Palpitations—Formoterol—chronic obstructive pulmonary disease	2.91e-05	0.000857	CcSEcCtD
Salmeterol—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	2.88e-05	0.00085	CcSEcCtD
Salmeterol—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	2.88e-05	0.00085	CcSEcCtD
Salmeterol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	2.88e-05	0.00965	CbGpPWpGaD
Salmeterol—Cough—Arformoterol—chronic obstructive pulmonary disease	2.87e-05	0.000846	CcSEcCtD
Salmeterol—Cough—Formoterol—chronic obstructive pulmonary disease	2.87e-05	0.000846	CcSEcCtD
Salmeterol—Agitation—Salbutamol—chronic obstructive pulmonary disease	2.85e-05	0.000842	CcSEcCtD
Salmeterol—Palpitations—Montelukast—chronic obstructive pulmonary disease	2.85e-05	0.000839	CcSEcCtD
Salmeterol—Constipation—Tiotropium—chronic obstructive pulmonary disease	2.84e-05	0.000839	CcSEcCtD
Salmeterol—Hypertension—Arformoterol—chronic obstructive pulmonary disease	2.84e-05	0.000837	CcSEcCtD
Salmeterol—Hypertension—Formoterol—chronic obstructive pulmonary disease	2.84e-05	0.000837	CcSEcCtD
Salmeterol—Angioedema—Salbutamol—chronic obstructive pulmonary disease	2.84e-05	0.000837	CcSEcCtD
Salmeterol—Cough—Montelukast—chronic obstructive pulmonary disease	2.81e-05	0.000829	CcSEcCtD
Salmeterol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Malaise—Salbutamol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Myalgia—Formoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Chest pain—Formoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Chest pain—Arformoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Myalgia—Arformoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Arthralgia—Formoterol—chronic obstructive pulmonary disease	2.8e-05	0.000826	CcSEcCtD
Salmeterol—Anxiety—Arformoterol—chronic obstructive pulmonary disease	2.79e-05	0.000823	CcSEcCtD
Salmeterol—Anxiety—Formoterol—chronic obstructive pulmonary disease	2.79e-05	0.000823	CcSEcCtD
Salmeterol—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	2.79e-05	0.000822	CcSEcCtD
Salmeterol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	2.79e-05	0.000822	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	2.78e-05	0.00082	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	2.78e-05	0.00082	CcSEcCtD
Salmeterol—Discomfort—Formoterol—chronic obstructive pulmonary disease	2.77e-05	0.000816	CcSEcCtD
Salmeterol—Discomfort—Arformoterol—chronic obstructive pulmonary disease	2.77e-05	0.000816	CcSEcCtD
Salmeterol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	2.74e-05	0.000809	CcSEcCtD
Salmeterol—Myalgia—Montelukast—chronic obstructive pulmonary disease	2.74e-05	0.000809	CcSEcCtD
Salmeterol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	2.74e-05	0.000809	CcSEcCtD
Salmeterol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	2.74e-05	0.000808	CcSEcCtD
Salmeterol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	2.74e-05	0.000808	CcSEcCtD
Salmeterol—Anxiety—Montelukast—chronic obstructive pulmonary disease	2.73e-05	0.000806	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	2.72e-05	0.000803	CcSEcCtD
Salmeterol—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	2.72e-05	0.000802	CcSEcCtD
Salmeterol—Cough—Salbutamol—chronic obstructive pulmonary disease	2.71e-05	0.000799	CcSEcCtD
Salmeterol—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	2.69e-05	0.009	CbGpPWpGaD
Salmeterol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	2.68e-05	0.000792	CcSEcCtD
Salmeterol—Oedema—Arformoterol—chronic obstructive pulmonary disease	2.68e-05	0.000792	CcSEcCtD
Salmeterol—Oedema—Formoterol—chronic obstructive pulmonary disease	2.68e-05	0.000792	CcSEcCtD
Salmeterol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	2.68e-05	0.000792	CcSEcCtD
Salmeterol—Hypertension—Salbutamol—chronic obstructive pulmonary disease	2.68e-05	0.000791	CcSEcCtD
Salmeterol—Infection—Formoterol—chronic obstructive pulmonary disease	2.67e-05	0.000786	CcSEcCtD
Salmeterol—Infection—Arformoterol—chronic obstructive pulmonary disease	2.67e-05	0.000786	CcSEcCtD
Salmeterol—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	2.64e-05	0.00078	CcSEcCtD
Salmeterol—Chest pain—Salbutamol—chronic obstructive pulmonary disease	2.64e-05	0.00078	CcSEcCtD
Salmeterol—Myalgia—Salbutamol—chronic obstructive pulmonary disease	2.64e-05	0.00078	CcSEcCtD
Salmeterol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	2.64e-05	0.000779	CcSEcCtD
Salmeterol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	2.63e-05	0.000777	CcSEcCtD
Salmeterol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	2.63e-05	0.000776	CcSEcCtD
Salmeterol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	2.63e-05	0.000776	CcSEcCtD
Salmeterol—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	2.63e-05	0.000775	CcSEcCtD
Salmeterol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	2.63e-05	0.000775	CcSEcCtD
Salmeterol—Oedema—Montelukast—chronic obstructive pulmonary disease	2.63e-05	0.000775	CcSEcCtD
Salmeterol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	2.62e-05	0.000772	CcSEcCtD
Salmeterol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	2.62e-05	0.000772	CcSEcCtD
Salmeterol—Discomfort—Salbutamol—chronic obstructive pulmonary disease	2.61e-05	0.00077	CcSEcCtD
Salmeterol—Infection—Montelukast—chronic obstructive pulmonary disease	2.61e-05	0.00077	CcSEcCtD
Salmeterol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	2.61e-05	0.000769	CcSEcCtD
Salmeterol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	2.61e-05	0.000769	CcSEcCtD
Salmeterol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	2.6e-05	0.000766	CcSEcCtD
Salmeterol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	2.58e-05	0.000762	CcSEcCtD
Salmeterol—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	2.58e-05	0.000761	CcSEcCtD
Salmeterol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	2.58e-05	0.00076	CcSEcCtD
Salmeterol—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	2.57e-05	0.00862	CbGpPWpGaD
Salmeterol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	2.55e-05	0.000753	CcSEcCtD
Salmeterol—Oedema—Salbutamol—chronic obstructive pulmonary disease	2.53e-05	0.000747	CcSEcCtD
Salmeterol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	2.53e-05	0.000747	CcSEcCtD
Salmeterol—Infection—Salbutamol—chronic obstructive pulmonary disease	2.52e-05	0.000742	CcSEcCtD
Salmeterol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	2.48e-05	0.000733	CcSEcCtD
Salmeterol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	2.47e-05	0.000729	CcSEcCtD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	2.47e-05	0.00829	CbGpPWpGaD
Salmeterol—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	2.47e-05	0.00827	CbGpPWpGaD
Salmeterol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	2.46e-05	0.000726	CcSEcCtD
Salmeterol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	2.45e-05	0.000723	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	2.44e-05	0.000721	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	2.44e-05	0.000721	CcSEcCtD
Salmeterol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	2.43e-05	0.000716	CcSEcCtD
Salmeterol—Insomnia—Formoterol—chronic obstructive pulmonary disease	2.43e-05	0.000716	CcSEcCtD
Salmeterol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	2.41e-05	0.000712	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	2.39e-05	0.000706	CcSEcCtD
Salmeterol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	2.39e-05	0.000706	CcSEcCtD
Salmeterol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	2.39e-05	0.000706	CcSEcCtD
Salmeterol—Insomnia—Montelukast—chronic obstructive pulmonary disease	2.38e-05	0.000701	CcSEcCtD
Salmeterol—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	2.37e-05	0.00796	CbGpPWpGaD
Salmeterol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	2.36e-05	0.000697	CcSEcCtD
Salmeterol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	2.36e-05	0.000697	CcSEcCtD
Salmeterol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	2.36e-05	0.000696	CcSEcCtD
Salmeterol—Injury—Prednisone—chronic obstructive pulmonary disease	2.34e-05	0.00069	CcSEcCtD
Salmeterol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	2.33e-05	0.000688	CcSEcCtD
Salmeterol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	2.31e-05	0.000682	CcSEcCtD
Salmeterol—Fatigue—Formoterol—chronic obstructive pulmonary disease	2.31e-05	0.000682	CcSEcCtD
Salmeterol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	2.31e-05	0.000682	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	2.31e-05	0.000681	CcSEcCtD
Salmeterol—Pain—Formoterol—chronic obstructive pulmonary disease	2.29e-05	0.000677	CcSEcCtD
Salmeterol—Constipation—Formoterol—chronic obstructive pulmonary disease	2.29e-05	0.000677	CcSEcCtD
Salmeterol—Constipation—Arformoterol—chronic obstructive pulmonary disease	2.29e-05	0.000677	CcSEcCtD
Salmeterol—Pain—Arformoterol—chronic obstructive pulmonary disease	2.29e-05	0.000677	CcSEcCtD
Salmeterol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	2.29e-05	0.000676	CcSEcCtD
Salmeterol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	2.28e-05	0.000671	CcSEcCtD
Salmeterol—Fatigue—Montelukast—chronic obstructive pulmonary disease	2.27e-05	0.000668	CcSEcCtD
Salmeterol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	2.26e-05	0.000666	CcSEcCtD
Salmeterol—CYP3A5—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.26e-05	0.00756	CbGpPWpGaD
Salmeterol—Pain—Montelukast—chronic obstructive pulmonary disease	2.25e-05	0.000663	CcSEcCtD
Salmeterol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	2.24e-05	0.000661	CcSEcCtD
Salmeterol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	2.23e-05	0.000658	CcSEcCtD
Salmeterol—Rash—Aminophylline—chronic obstructive pulmonary disease	2.22e-05	0.000656	CcSEcCtD
Salmeterol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	2.22e-05	0.000655	CcSEcCtD
Salmeterol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	2.22e-05	0.00743	CbGpPWpGaD
Salmeterol—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	2.21e-05	0.000653	CcSEcCtD
Salmeterol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	2.21e-05	0.000652	CcSEcCtD
Salmeterol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	2.21e-05	0.000652	CcSEcCtD
Salmeterol—CYP2C8—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	2.21e-05	0.00741	CbGpPWpGaD
Salmeterol—Headache—Aminophylline—chronic obstructive pulmonary disease	2.21e-05	0.000652	CcSEcCtD
Salmeterol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.2e-05	0.00739	CbGpPWpGaD
Salmeterol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	2.2e-05	0.000649	CcSEcCtD
Salmeterol—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	2.19e-05	0.000647	CcSEcCtD
Salmeterol—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	2.19e-05	0.000647	CcSEcCtD
Salmeterol—CYP3A7—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	2.19e-05	0.00733	CbGpPWpGaD
Salmeterol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	2.18e-05	0.000644	CcSEcCtD
Salmeterol—CYP3A5—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	2.18e-05	0.00729	CbGpPWpGaD
Salmeterol—Pain—Salbutamol—chronic obstructive pulmonary disease	2.17e-05	0.000639	CcSEcCtD
Salmeterol—Constipation—Salbutamol—chronic obstructive pulmonary disease	2.17e-05	0.000639	CcSEcCtD
Salmeterol—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	2.15e-05	0.000634	CcSEcCtD
Salmeterol—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	2.14e-05	0.00719	CbGpPWpGaD
Salmeterol—Urticaria—Formoterol—chronic obstructive pulmonary disease	2.13e-05	0.000629	CcSEcCtD
Salmeterol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	2.13e-05	0.000629	CcSEcCtD
Salmeterol—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	2.12e-05	0.000626	CcSEcCtD
Salmeterol—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	2.12e-05	0.000626	CcSEcCtD
Salmeterol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	2.12e-05	0.000626	CcSEcCtD
Salmeterol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	2.12e-05	0.000626	CcSEcCtD
Salmeterol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	2.11e-05	0.000624	CcSEcCtD
Salmeterol—Rash—Tiotropium—chronic obstructive pulmonary disease	2.1e-05	0.000618	CcSEcCtD
Salmeterol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	2.09e-05	0.000618	CcSEcCtD
Salmeterol—Nausea—Aminophylline—chronic obstructive pulmonary disease	2.09e-05	0.000618	CcSEcCtD
Salmeterol—Urticaria—Montelukast—chronic obstructive pulmonary disease	2.09e-05	0.000616	CcSEcCtD
Salmeterol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	2.09e-05	0.000616	CcSEcCtD
Salmeterol—Headache—Tiotropium—chronic obstructive pulmonary disease	2.08e-05	0.000614	CcSEcCtD
Salmeterol—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	2.08e-05	0.000613	CcSEcCtD
Salmeterol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	2.08e-05	0.000613	CcSEcCtD
Salmeterol—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	2.07e-05	0.000611	CcSEcCtD
Salmeterol—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	2.06e-05	0.0069	CbGpPWpGaD
Salmeterol—Irritability—Prednisone—chronic obstructive pulmonary disease	2.05e-05	0.000605	CcSEcCtD
Salmeterol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	2.01e-05	0.000594	CcSEcCtD
Salmeterol—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	2e-05	0.000591	CcSEcCtD
Salmeterol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	2e-05	0.000591	CcSEcCtD
Salmeterol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	1.98e-05	0.000583	CcSEcCtD
Salmeterol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	1.98e-05	0.000583	CcSEcCtD
Salmeterol—Nausea—Tiotropium—chronic obstructive pulmonary disease	1.97e-05	0.000583	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	1.95e-05	0.00655	CbGpPWpGaD
Salmeterol—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	1.95e-05	0.00654	CbGpPWpGaD
Salmeterol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	1.94e-05	0.000571	CcSEcCtD
Salmeterol—Asthenia—Formoterol—chronic obstructive pulmonary disease	1.93e-05	0.000568	CcSEcCtD
Salmeterol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	1.93e-05	0.000568	CcSEcCtD
Salmeterol—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	1.91e-05	0.0064	CbGpPWpGaD
Salmeterol—Asthenia—Montelukast—chronic obstructive pulmonary disease	1.89e-05	0.000556	CcSEcCtD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	1.88e-05	0.00632	CbGpPWpGaD
Salmeterol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	1.87e-05	0.000551	CcSEcCtD
Salmeterol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	1.84e-05	0.000542	CcSEcCtD
Salmeterol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	1.84e-05	0.000542	CcSEcCtD
Salmeterol—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	1.83e-05	0.000539	CcSEcCtD
Salmeterol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	1.82e-05	0.000536	CcSEcCtD
Salmeterol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	1.8e-05	0.00053	CcSEcCtD
Salmeterol—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.8e-05	0.00602	CbGpPWpGaD
Salmeterol—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	1.79e-05	0.00601	CbGpPWpGaD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	1.79e-05	0.00599	CbGpPWpGaD
Salmeterol—Dizziness—Formoterol—chronic obstructive pulmonary disease	1.77e-05	0.000523	CcSEcCtD
Salmeterol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	1.77e-05	0.000523	CcSEcCtD
Salmeterol—Dizziness—Montelukast—chronic obstructive pulmonary disease	1.74e-05	0.000513	CcSEcCtD
Salmeterol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	1.73e-05	0.000511	CcSEcCtD
Salmeterol—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	1.72e-05	0.00578	CbGpPWpGaD
Salmeterol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	1.71e-05	0.000503	CcSEcCtD
Salmeterol—Vomiting—Formoterol—chronic obstructive pulmonary disease	1.71e-05	0.000503	CcSEcCtD
Salmeterol—Rash—Formoterol—chronic obstructive pulmonary disease	1.69e-05	0.000499	CcSEcCtD
Salmeterol—Rash—Arformoterol—chronic obstructive pulmonary disease	1.69e-05	0.000499	CcSEcCtD
Salmeterol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	1.69e-05	0.000499	CcSEcCtD
Salmeterol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	1.69e-05	0.000499	CcSEcCtD
Salmeterol—Headache—Arformoterol—chronic obstructive pulmonary disease	1.68e-05	0.000496	CcSEcCtD
Salmeterol—Headache—Formoterol—chronic obstructive pulmonary disease	1.68e-05	0.000496	CcSEcCtD
Salmeterol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	1.68e-05	0.000494	CcSEcCtD
Salmeterol—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	1.68e-05	0.000494	CcSEcCtD
Salmeterol—Vomiting—Montelukast—chronic obstructive pulmonary disease	1.67e-05	0.000493	CcSEcCtD
Salmeterol—Rash—Montelukast—chronic obstructive pulmonary disease	1.66e-05	0.000489	CcSEcCtD
Salmeterol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	1.66e-05	0.000488	CcSEcCtD
Salmeterol—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	1.65e-05	0.000487	CcSEcCtD
Salmeterol—Headache—Montelukast—chronic obstructive pulmonary disease	1.65e-05	0.000486	CcSEcCtD
Salmeterol—Angioedema—Prednisolone—chronic obstructive pulmonary disease	1.63e-05	0.00048	CcSEcCtD
Salmeterol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	1.61e-05	0.00541	CbGpPWpGaD
Salmeterol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	1.61e-05	0.000475	CcSEcCtD
Salmeterol—Malaise—Prednisolone—chronic obstructive pulmonary disease	1.61e-05	0.000474	CcSEcCtD
Salmeterol—CYP2C8—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	1.61e-05	0.00538	CbGpPWpGaD
Salmeterol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.6e-05	0.00537	CbGpPWpGaD
Salmeterol—Rash—Salbutamol—chronic obstructive pulmonary disease	1.6e-05	0.000471	CcSEcCtD
Salmeterol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	1.6e-05	0.000471	CcSEcCtD
Salmeterol—Nausea—Formoterol—chronic obstructive pulmonary disease	1.59e-05	0.00047	CcSEcCtD
Salmeterol—Nausea—Arformoterol—chronic obstructive pulmonary disease	1.59e-05	0.00047	CcSEcCtD
Salmeterol—Headache—Salbutamol—chronic obstructive pulmonary disease	1.59e-05	0.000468	CcSEcCtD
Salmeterol—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.58e-05	0.0053	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.58e-05	0.0053	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.56e-05	0.00524	CbGpPWpGaD
Salmeterol—Nausea—Montelukast—chronic obstructive pulmonary disease	1.56e-05	0.000461	CcSEcCtD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	1.55e-05	0.00519	CbGpPWpGaD
Salmeterol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	1.54e-05	0.000453	CcSEcCtD
Salmeterol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	1.52e-05	0.0051	CbGpPWpGaD
Salmeterol—Nausea—Salbutamol—chronic obstructive pulmonary disease	1.5e-05	0.000444	CcSEcCtD
Salmeterol—Discomfort—Prednisolone—chronic obstructive pulmonary disease	1.5e-05	0.000442	CcSEcCtD
Salmeterol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	1.48e-05	0.00495	CbGpPWpGaD
Salmeterol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	1.46e-05	0.000431	CcSEcCtD
Salmeterol—Oedema—Prednisolone—chronic obstructive pulmonary disease	1.45e-05	0.000429	CcSEcCtD
Salmeterol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	1.45e-05	0.000429	CcSEcCtD
Salmeterol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	1.42e-05	0.000418	CcSEcCtD
Salmeterol—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.39e-05	0.00465	CbGpPWpGaD
Salmeterol—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.37e-05	0.00459	CbGpPWpGaD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.35e-05	0.00452	CbGpPWpGaD
Salmeterol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	1.34e-05	0.000396	CcSEcCtD
Salmeterol—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	1.33e-05	0.000392	CcSEcCtD
Salmeterol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	1.31e-05	0.000388	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.31e-05	0.0044	CbGpPWpGaD
Salmeterol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	1.3e-05	0.000385	CcSEcCtD
Salmeterol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	1.3e-05	0.000384	CcSEcCtD
Salmeterol—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.00435	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.00434	CbGpPWpGaD
Salmeterol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	1.29e-05	0.000382	CcSEcCtD
Salmeterol—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	1.27e-05	0.00425	CbGpPWpGaD
Salmeterol—Pain—Prednisolone—chronic obstructive pulmonary disease	1.24e-05	0.000367	CcSEcCtD
Salmeterol—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	1.2e-05	0.000354	CcSEcCtD
Salmeterol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	1.2e-05	0.000353	CcSEcCtD
Salmeterol—Agitation—Prednisone—chronic obstructive pulmonary disease	1.19e-05	0.000351	CcSEcCtD
Salmeterol—Angioedema—Prednisone—chronic obstructive pulmonary disease	1.18e-05	0.000349	CcSEcCtD
Salmeterol—Malaise—Prednisone—chronic obstructive pulmonary disease	1.17e-05	0.000344	CcSEcCtD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.16e-05	0.00387	CbGpPWpGaD
Salmeterol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	1.15e-05	0.000341	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.14e-05	0.00383	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.13e-05	0.00378	CbGpPWpGaD
Salmeterol—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.12e-05	0.00377	CbGpPWpGaD
Salmeterol—Hypertension—Prednisone—chronic obstructive pulmonary disease	1.12e-05	0.00033	CcSEcCtD
Salmeterol—Myalgia—Prednisone—chronic obstructive pulmonary disease	1.1e-05	0.000325	CcSEcCtD
Salmeterol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	1.1e-05	0.000325	CcSEcCtD
Salmeterol—Anxiety—Prednisone—chronic obstructive pulmonary disease	1.1e-05	0.000324	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.1e-05	0.00367	CbGpPWpGaD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	1.09e-05	0.000323	CcSEcCtD
Salmeterol—Discomfort—Prednisone—chronic obstructive pulmonary disease	1.09e-05	0.000321	CcSEcCtD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.08e-05	0.00362	CbGpPWpGaD
Salmeterol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	1.07e-05	0.000316	CcSEcCtD
Salmeterol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	1.06e-05	0.000311	CcSEcCtD
Salmeterol—Oedema—Prednisone—chronic obstructive pulmonary disease	1.06e-05	0.000311	CcSEcCtD
Salmeterol—Infection—Prednisone—chronic obstructive pulmonary disease	1.05e-05	0.000309	CcSEcCtD
Salmeterol—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	1.05e-05	0.00351	CbGpPWpGaD
Salmeterol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	1.04e-05	0.000305	CcSEcCtD
Salmeterol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	1.03e-05	0.000304	CcSEcCtD
Salmeterol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	1.03e-05	0.000303	CcSEcCtD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	1.03e-05	0.00344	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	1.01e-05	0.00339	CbGpPWpGaD
Salmeterol—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.01e-05	0.00337	CbGpPWpGaD
Salmeterol—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.93e-06	0.00333	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.9e-06	0.00332	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.78e-06	0.00328	CbGpPWpGaD
Salmeterol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.62e-06	0.000284	CcSEcCtD
Salmeterol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.61e-06	0.000283	CcSEcCtD
Salmeterol—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.55e-06	0.000282	CcSEcCtD
Salmeterol—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.54e-06	0.0032	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.49e-06	0.00318	CbGpPWpGaD
Salmeterol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.48e-06	0.00028	CcSEcCtD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	9.41e-06	0.00315	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.36e-06	0.00314	CbGpPWpGaD
Salmeterol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	9.3e-06	0.000274	CcSEcCtD
Salmeterol—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.21e-06	0.00309	CbGpPWpGaD
Salmeterol—Rash—Prednisolone—chronic obstructive pulmonary disease	9.16e-06	0.00027	CcSEcCtD
Salmeterol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.15e-06	0.00027	CcSEcCtD
Salmeterol—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.1e-06	0.000269	CcSEcCtD
Salmeterol—Headache—Prednisolone—chronic obstructive pulmonary disease	9.1e-06	0.000269	CcSEcCtD
Salmeterol—Constipation—Prednisone—chronic obstructive pulmonary disease	9.03e-06	0.000266	CcSEcCtD
Salmeterol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	8.8e-06	0.00295	CbGpPWpGaD
Salmeterol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.7e-06	0.000257	CcSEcCtD
Salmeterol—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.64e-06	0.000255	CcSEcCtD
Salmeterol—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.63e-06	0.000255	CcSEcCtD
Salmeterol—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.39e-06	0.000247	CcSEcCtD
Salmeterol—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.35e-06	0.000246	CcSEcCtD
Salmeterol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.35e-06	0.000246	CcSEcCtD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	8.31e-06	0.00279	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.22e-06	0.00276	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.11e-06	0.00272	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.92e-06	0.00265	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.81e-06	0.00262	CbGpPWpGaD
Salmeterol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.78e-06	0.000229	CcSEcCtD
Salmeterol—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	7.68e-06	0.00257	CbGpPWpGaD
Salmeterol—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.58e-06	0.000223	CcSEcCtD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.45e-06	0.0025	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.35e-06	0.00246	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.28e-06	0.00244	CbGpPWpGaD
Salmeterol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.23e-06	0.000213	CcSEcCtD
Salmeterol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.2e-06	0.00241	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.18e-06	0.00241	CbGpPWpGaD
Salmeterol—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.98e-06	0.000206	CcSEcCtD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.96e-06	0.00233	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.9e-06	0.00231	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.86e-06	0.0023	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.8e-06	0.00228	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.76e-06	0.00227	CbGpPWpGaD
Salmeterol—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.71e-06	0.000198	CcSEcCtD
Salmeterol—Rash—Prednisone—chronic obstructive pulmonary disease	6.66e-06	0.000196	CcSEcCtD
Salmeterol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.65e-06	0.000196	CcSEcCtD
Salmeterol—Headache—Prednisone—chronic obstructive pulmonary disease	6.62e-06	0.000195	CcSEcCtD
Salmeterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.61e-06	0.00222	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	6.48e-06	0.00217	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.3e-06	0.00211	CbGpPWpGaD
Salmeterol—Nausea—Prednisone—chronic obstructive pulmonary disease	6.27e-06	0.000185	CcSEcCtD
Salmeterol—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.22e-06	0.00208	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	6.17e-06	0.00207	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.04e-06	0.00202	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.98e-06	0.002	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.89e-06	0.00198	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.66e-06	0.0019	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.6e-06	0.00188	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	5.55e-06	0.00186	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.31e-06	0.00178	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.25e-06	0.00176	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.09e-06	0.0017	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.97e-06	0.00167	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	4.95e-06	0.00166	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.93e-06	0.00165	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	4.81e-06	0.00161	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.6e-06	0.00154	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.51e-06	0.00151	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.41e-06	0.00148	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.37e-06	0.00146	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.35e-06	0.00146	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.31e-06	0.00145	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.68e-06	0.00123	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.68e-06	0.00123	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.63e-06	0.00122	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	3.58e-06	0.0012	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.5e-06	0.00117	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.43e-06	0.00115	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.38e-06	0.00113	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.34e-06	0.00112	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.32e-06	0.00111	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.31e-06	0.00111	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.21e-06	0.00107	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.18e-06	0.00107	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.16e-06	0.00106	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.16e-06	0.00106	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	3.1e-06	0.00104	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.88e-06	0.000965	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.79e-06	0.000934	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.7e-06	0.000906	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	2.67e-06	0.000895	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.67e-06	0.000894	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.66e-06	0.000893	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.58e-06	0.000865	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.53e-06	0.000848	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	2.44e-06	0.000817	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.44e-06	0.000817	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.29e-06	0.000769	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.25e-06	0.000753	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.21e-06	0.000742	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.95e-06	0.000655	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.95e-06	0.000653	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.93e-06	0.000647	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.87e-06	0.000628	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.85e-06	0.000619	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.81e-06	0.000608	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.76e-06	0.000591	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.72e-06	0.000577	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-06	0.000573	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.69e-06	0.000567	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	1.67e-06	0.000561	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.66e-06	0.000557	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.63e-06	0.000547	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.62e-06	0.000544	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.56e-06	0.000523	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.55e-06	0.000518	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	1.53e-06	0.000512	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.51e-06	0.000505	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.49e-06	0.000501	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.41e-06	0.000471	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.37e-06	0.000458	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.36e-06	0.000455	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.35e-06	0.000454	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.34e-06	0.000448	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.31e-06	0.000438	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.24e-06	0.000417	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.22e-06	0.000407	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.18e-06	0.000395	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.17e-06	0.000393	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.16e-06	0.000388	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	1.11e-06	0.000372	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.08e-06	0.000361	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	1.06e-06	0.000356	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.02e-06	0.000342	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1e-06	0.000335	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.54e-07	0.00032	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.11e-07	0.000305	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.08e-07	0.000304	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.98e-07	0.000301	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.19e-07	0.000275	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.08e-07	0.000271	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	8.02e-07	0.000269	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.68e-07	0.000257	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	7.67e-07	0.000257	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.55e-07	0.000253	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.31e-07	0.000245	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	6.95e-07	0.000233	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	6.64e-07	0.000223	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.56e-07	0.00022	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.3e-07	0.000211	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.21e-07	0.000208	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.02e-07	0.000202	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.91e-07	0.000198	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.79e-07	0.000194	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.48e-07	0.000184	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.96e-07	0.000166	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.54e-07	0.000152	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.73e-07	0.000125	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.57e-07	0.00012	CbGpPWpGaD
